The FDA rejected Pain’s lead asset and said the drug’s negatives outweigh its positives.
"The data submitted in [the] NDA do not support the conclusion that the benefits of [REMOXY] extended-release capsules outweigh the risks,” the FDA said in a statement.
Why It’s Important
As an abuse-deterring, extended-release form of oxycodone, Remoxy was Pain Therapeutics’ answer to the opioid crisis.
"This is a bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction," Pain Therapeutics CEO Remi Barbier said in a statement.
"We have an innovative drug with a social purpose, and a staggering amount of data that easily supports best-in-class abuse deterrence versus OxyContin. We relied on the criteria of a fair, neutral and impartial regulatory review, as any sponsor would. Instead, I believe REMOXY received an ideological judgement [sic] call that is vague in nature but conclusive in its damaging effects."
Pain Therapeutics said it will redirect its resources to advance its Alzheimer’s assets.
"Alzheimer's disease is a therapeutic indication with a profound need for new treatments," Barbier said. "A reorganization of the company represents a natural and timely evolution of the strength of our program in Alzheimer's disease."
Details of the plan will be discussed on a conference call in the coming weeks, according to Pain Therapeutics.
Analyst: Durect's Phase 2 Trials Are An Entry Point For Investors
Pain Therapeutics Shares Double On Clinical Study Data
See more from Benzinga
- Goldman Sachs Cuts Madrigal Pharma To Neutral Given No Near-Term Catalysts
- Sprint, T-Mobile Merger Looks More Likely As DOJ Calls For Just 3 Leading 5G Carriers
- Intercept Pharma Notches 2 Upgrades On Ocaliva Prospects
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.